- Home
- MRCC vs ENGN Comparison
MRCC vs ENGN Comparison
Compare MRCC & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRCC
- ENGN
- Stock Information
- Founded
- MRCC 2011
- ENGN 1999
- Country
- MRCC United States
- ENGN Canada
- Employees
- MRCC N/A
- ENGN N/A
- Industry
- MRCC Investment Managers
- ENGN
- Sector
- MRCC Finance
- ENGN
- Exchange
- MRCC Nasdaq
- ENGN Nasdaq
- Market Cap
- MRCC 176.4M
- ENGN 191.1M
- IPO Year
- MRCC 2012
- ENGN N/A
- Fundamental
- Price
- MRCC $6.40
- ENGN $3.51
- Analyst Decision
- MRCC Hold
- ENGN Buy
- Analyst Count
- MRCC 1
- ENGN 7
- Target Price
- MRCC $8.00
- ENGN $23.29
- AVG Volume (30 Days)
- MRCC 84.9K
- ENGN 76.2K
- Earning Date
- MRCC 08-06-2025
- ENGN 09-09-2025
- Dividend Yield
- MRCC 15.75%
- ENGN N/A
- EPS Growth
- MRCC 3301.50
- ENGN N/A
- EPS
- MRCC 0.32
- ENGN N/A
- Revenue
- MRCC $56,983,000.00
- ENGN N/A
- Revenue This Year
- MRCC N/A
- ENGN N/A
- Revenue Next Year
- MRCC N/A
- ENGN N/A
- P/E Ratio
- MRCC $19.54
- ENGN N/A
- Revenue Growth
- MRCC N/A
- ENGN N/A
- 52 Week Low
- MRCC $6.11
- ENGN $2.65
- 52 Week High
- MRCC $8.85
- ENGN $11.00
- Technical
- Relative Strength Index (RSI)
- MRCC 48.93
- ENGN 48.11
- Support Level
- MRCC $6.32
- ENGN $3.25
- Resistance Level
- MRCC $6.50
- ENGN $3.98
- Average True Range (ATR)
- MRCC 0.16
- ENGN 0.26
- MACD
- MRCC 0.01
- ENGN -0.00
- Stochastic Oscillator
- MRCC 47.92
- ENGN 54.37
About MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.